Lexology January 22, 2025
Casimir Jones SC

Click here to listen to the audio.

The process of transforming cutting-edge academic research into life-changing therapies is often described as moving from bench to market. Joining us today is Elizabeth Douville, President and CEO of Iricor, a cancerology and immunology research valorization center based at the University of Montreal.

Elizabeth is a leader who connects academic, industry and government ecosystems. She has a passion for scientific research and a track record of turning university innovations into biotech companies. She’s a force to be reckoned with in the life sciences.

In this episode we’ll talk about how Iricor is tackling drug development, de-risking early stage innovation and commercializing promising therapies. We’ll also talk about bridging the infamous “Valley of Death”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Are third-party telehealth prescriptions of GLP-1s safe?
Study sheds new light on brain evolution
Merck Is Embracing AI, But ‘We Always Have a Human in the Loop,’ Exec Says
Do GLP-1s curb alcohol consumption?
The ‘Hidden Gem’ Healthtech Areas VCs Have Their Eye On

Share This Article